Form 8-K · Current Report · Filed 2026-08-04

Gilead Sciences Reports Q2 2026 Financial Results with Significant Acquisition-Related Expenses

Gilead Sciences, Inc. reported its financial results for the quarter ended June 30, 2026, showing a 10% increase in total revenues to $7.8 billion. Product sales excluding Veklury increased by 10% to $7.6 billion, driven by higher sales of HIV products, Trodelvy, and Livdelzi. However, the company reported a diluted loss per share of $(8.45) due to significant acquired in-process research and development expenses related to recent acquisitions, partially offset by higher revenues and lower income tax expense. Non-GAAP diluted loss per share was $(6.75). The company also provided updated full-year 2026 guidance, reflecting the impact of these acquisitions.